ALKSMEDIUM SIGNALFINANCIAL10-K

ALKS experienced declining profitability with operating income falling 40% as substantially higher R&D spending offset revenue performance.

The company appears to be in an investment phase, with R&D expenses growing 32% while profitability metrics declined significantly. The increased interest expense suggests higher borrowing costs, though total debt actually decreased, indicating potential refinancing at less favorable terms.

Comparing 2026-02-25 vs 2025-02-12View on EDGAR →
FINANCIAL ANALYSIS

ALKS showed a mixed financial picture with declining profitability as operating income fell 40% and net income dropped 34%, primarily driven by substantially higher R&D spending that grew 32%. However, the balance sheet strengthened considerably with current assets expanding 36%, cash growing 34%, and stockholders' equity increasing 24%, while total debt declined 19%. This suggests the company is investing heavily in development while maintaining a solid financial foundation, though at the cost of near-term earnings performance.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
+76.6%
$13.0M→$23.0M

Interest expense surged 76.6% — significant debt increase or rising rates materially impacting earnings.

Operating Income
P&L
-39.6%
$420.6M→$254.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
+36.3%
$1.4B→$1.9B

Current assets grew 36.3% — improving short-term liquidity or inventory/receivables build.

Net Income
P&L
-34.2%
$367.1M→$241.7M

Net income declined 34.2% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
+33.5%
$291.1M→$388.6M

Cash position surged 33.5% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
+32.1%
$245.3M→$324.0M

R&D investment increased 32.1% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
+24.2%
$1.5B→$1.8B

Equity base grew 24.2% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+21%
$2.1B→$2.5B

Asset base grew 21% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
+20.7%
$33.5M→$40.4M

Capex increased 20.7% — ongoing investment in capacity or infrastructure for future growth.

Total Debt
Balance Sheet
-18.9%
$349.9M→$283.7M

Debt reduced 18.9% — deleveraging strengthens balance sheet and reduces financial risk.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-02-12
ADDED
As of February 20, 2026, 166,649,934 ordinary shares were outstanding.
Securities and Exchange Commission ( SEC ) and other government agencies could negatively impact our business; we may not be able to successfully expand our research and development ( R D ) pipeline or our commercial product portfolio, which could limit our growth potential; we are subject to risks related to the manufacture of our products; we rely on third parties to provide goods and services in connection with the manufacture and distribution of our products; LUMRYZ is a controlled substance subject to U.S.
government or governments of other nations, could have an adverse effect on our business, results of operations, or financial condition.
); ANTABUSE Teva Women s Health, Inc.; AUBAGIO and LEMTRADA Sanofi Societe Anonyme France; AVONEX , PLEGRIDY , TECFIDERA , TYSABRI and VUMERITY Biogen MA Inc.
(together with its affiliates, Biogen ); BETASERON Bayer Pharma AG; BRIXADI Braeburn Inc.; BRIUMVI TG Therapeutics, Inc.; BUNAVAIL TM BioDelivery Sciences; CAMPRAL Merck Sante;COPAXONE and UZEDY Teva Pharmaceutical Industries Ltd.
+7 more — sign up free →
REMOVED
As of February 7, 2025, 162,614,067 ordinary shares were outstanding.
federal and Irish tax purposes as we anticipate, we and/or our shareholders could be subject to significant tax liabilities; 4 the market price of our ordinary shares has been volatile and may continue to be volatile in the future, and could decline significantly; our business could be negatively affected as a result of the actions of activist shareholders; and information security breaches and other disruptions could compromise our information and expose us to liability, which could cause our business and reputation to suffer.
( Acorda ); ANJESO Baudax Bio, Inc.; ANTABUSE Teva Women s Health, Inc.; AUBAGIO and LEMTRADA Sanofi Societe Anonyme France; AVONEX , PLEGRIDY , TECFIDERA , TYSABRI and VUMERITY Biogen MA Inc.
(together with its affiliates, Biogen ); BETASERON Bayer Pharma AG; BRIXADI Braeburn Inc.; BRIUMVI TG Therapeutics, Inc.; BUNAVAIL TM BioDelivery Sciences; CAMPRAL Merck Sante; CAPLYTA Intra-Cellular Therapies, Inc.; COPAXONE and UZEDY Teva Pharmaceutical Industries Ltd.
Lundbeck A/S plc; PERSERIS , SUBOXONE , SUBUTEX and SUBLOCADE Indivior plc (or its affiliates); RYKINDO Luye Pharma Group; VRAYLAR Forest Laboratories, LLC; COBENFY and ZEPOSIA Bristol-Myers Squibb Company; ZUBSOLV Orexo US, Inc.; and ZYPREXA and ZYPREXA RELPREVV Eli Lilly and Company ( Lilly ).
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →